A Phase 1 interventional study of VX-548 in Pain, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 7 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-29.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing suzetrigine in Pain — 4 open to participants now, 4 under way, 2 of them phase 3. suzetrigine · Pain.
Among the 21 studies testing suzetrigine in Pain, this one is the 13th largest by enrollment, is one of 4 that started in 2023, is one of 15 in phase 1, and was the 6th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →4 of the 21 studies testing suzetrigine in Pain are open now, in 1 country. Recruiting first, the newest first:
Hospital for Special Surgery, New York · Sites in United States
Ages 18–80 · Healthy volunteers
Hospital for Special Surgery, New York · Sites in United States
Ages 18–80 · Healthy volunteers
Stanford University · Sites in United States
Ages 18+
Jacob Lensing · Sites in United States
Ages 18–45
By country, each count listing its studies:
suzetrigine: first FDA approval 2025 (JOURNAVX). What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 4 started in 2023.
This study's enrollment of 38 is below the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 50 across the 21 interventional studies. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 6 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
26 studies in Pain by Vertex Pharmaceuticals Incorporated: none open now, none under way, none of them phase 3. Of 26 finished, 1 (4%) have results posted.
Among the 26 studies in Pain by Vertex Pharmaceuticals Incorporated, this one is the 14th largest by enrollment, is one of 5 that started in 2023, is one of 24 in phase 1, and was the 9th registered.
Vertex Pharmaceuticals Incorporated’s Pain studies by the year they started, since 2022.
2 of the studies testing suzetrigine in Pain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07226700Phase 3Hospital for Special Surgery, New YorkSuzetrigine in Total Hip Arthroplasty | 2027-11-01 |
| NCT07821931Stanford UniversitySuzetrigine in Tonsillectomy for Opioid-sparing Pain Management | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies testing suzetrigine in Pain, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 26 in Pain:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of VX-548 and its metabolite in participants with severe or moderate renal impairment and healthy participants.
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4) (A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).
Key Inclusion Criteria:
Cohorts 1 and 3: Participants with Severe or Moderate Renal Impairment
Cohorts 2 and 4: Matched Healthy Participants
Key Exclusion Criteria:
Cohorts 1 and 3: Participants with Severe or Moderate Renal Impairment
Cohorts 2 and 4: Matched Healthy Participants
All Cohorts:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of VX-548 in a fasted state.
Drug: VX-548
Healthy participants matched to cohort 1 will receive a single doses of VX-548 in a fasted state.
Drug: VX-548
Participants will receive a single dose of VX-548 in a fasted state.
Drug: VX-548
Healthy participants matched to cohort 3 will receive a single dose of VX-548 in a fasted state.
Drug: VX-548
Tablets for oral administration.
Also known as: Suzetrigine
Maximum Observed Plasma Concentration (Cmax) of VX-548 and its Metabolite
Time frame: Day 1 to Day 14
Area Under the Plasma Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-548 and its Metabolite
Time frame: Day 1 to Day 14
Apparent Clearance of VX-548
Time frame: Day 1 to Day 14
Apparent Renal Clearance of VX-548 and its Metabolite (CLr)
Time frame: Day 1 to Day 14
Apparent Non-Renal Clearance of VX-548
Time frame: Day 1 to Day 14
Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 to Day 23
Fraction Unbound (fu) for VX-548 and its Metabolite in Plasma
Time frame: Day 1 to Day 2
Unbound Area Under the Concentration Versus Time Curve of VX-548 and its Metabolite
Time frame: Day 1 to Day 14
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
No publications or documents are linked to this record.
Ran from Feb 2023 to primary completion in Mar 2024, 13 months.
Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 13 months is above that.
Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Suzetrigine
Vertex Pharmaceuticals Incorporated →